Haleon plc HLN.L
Composite 53/100; the shares have moved about 23% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Momentum ranks 43/100 — a slight mark against it.
Income ranks 63/100 — a moderate point in its favour. Quality ranks 59/100 — a slight point in its favour. Valuation ranks 58/100 — a slight point in its favour.
Momentum ranks 43/100 — a slight mark against it. Growth ranks 47/100 — a slight mark against it.
What the company does Haleon plc is a global consumer healthcare company with a portfolio of brands including Sensodyne, Centrum, Voltaren, and Theraflu. It operates across oral health, vitamins, respiratory, pain relief, and digestive health categories.
Key financials Haleon reports gross margins of 64.8%, operating margins of 23.2%, and net margins of 15.1%. ROE is 10.3%, ROA 4.7%, and ROCE 9.0%. Revenue growth is 0.6% while EPS growth is 92.0%. Debt/Equity stands at 0.52 and net debt/EBITDA at 2.66.
Stock health The stock shows mixed momentum: +11.68% over 3 months, +1.95% over 6 months, and +4.08% over 12 months. It is -8.74% below its 52-week high and has an RSI(14) of 67.00. The Sidravia Overall score is 54.0, with Valuation at 49.9 and Income at 68.2.
Price vs fair value The stock trades at a PREMIUM of 10.90% versus our fair-value estimate of 338.36 and at a discount of 9.33% versus the analyst 12-month target of 415.12. - Sales growth concerns overshadowed a profit beat (Reuters) - Quality of growth questioned by analysts (Proactive) - H1 earnings call highlighted margin and growth challenges (MarketBeat) - Comparisons to peers like Kenvue cited for margin pressure (Zacks)
Looking forward Forward P/E is 18.52 and PEG is 2.24, suggesting moderate valuation relative to growth. Analysts (count 17) see potential upside to 415.12, indicating a positive long-term outlook despite near-term headwinds.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.